Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bolder BioTechnology has obtained a $1.6 million Phase II continuing renewal small business innovation research grant from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health. Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Subscribe to our email newsletter
George Cox, president of Bolder BioTechnology, said: “We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS) for our long-acting beta interferon program. With previous funding from NINDS we developed a novel beta interferon analog that has a longer duration of action and more potent biological activity than existing beta interferon products in animals.
“The new grant award will be used to perform preclinical studies required by the FDA for filing an investigational new drug application to begin testing our long-acting beta interferon analog in people.”